Phase I/II Study of Dose-Escalated Hypofractionated Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of grade 3+ rectal toxicity
Common Terminology Criteria for Adverse Events (CTCAE) v3.0
Acute period (<3 months)
Yes
Andrew Loblaw, MD
Principal Investigator
Sunnybrook Health Sciences Centre
Canada: Health Canada
042-2010
NCT01146340
May 2010
Name | Location |
---|